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SUMMARY – The objective of this clinical update, based on recently published literature, was to 
discuss incidence and characteristics of the most relevant clinical adverse effects associated with local 
anesthetic and steroid use in regional anesthesia and treatment of acute or chronic pain. A compre-
hensive review of the English-language medical literature search utilizing PubMed, Ovid Medline® 
and Google Scholar from 2015 to 2018 was performed. This narrative review provides anesthesia 
practitioners with updated evidences on complications and contraindications of local anesthetic and 
steroid use with emphasis on current points of view regarding prevention, early diagnosis and treat-
ment of adverse events.
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Introduction
Local anesthetics (LAs) are generally safe and 
widely used medications and have been used in various 
clinical settings for decades. There are different routes 
of administration such as intravenous, topical, sub-
cutaneous and tissue infiltration, peripheral nerve 
blocks, epidural, spinal, caudal or intraarticular. The 
 introduction of new regional anesthetic techniques, 
emergence of new LAs, novel approaches in adminis-
tration such as high-volume tissue plane blocks and 
local infiltration analgesia (LIA) contribute to the in-
creasing use of local anesthetic. Local anesthetics and 
corticosteroids are frequently used in combination, 
mostly for diagnosis and treatment of musculoskeletal 
disturbances. Corticosteroids are mainly used because 
of their anti-inflammatory properties. Common routes 
of corticosteroid administration are intraarticular, epi-
dural, transforaminal as well as bursal or tendon sheath 
injections.
Increased use of LAs and steroids may increase in-
cidence of major adverse effects and complications. 
Although they are rare, anesthesia practitioners must 
be aware of potential catastrophic events. Complica-
tions of steroid injections can vary in severity from mi-
nor - such as skin depigmentation - to major - such as 
joint empyema. Also, LAs may cause complications in 
a broad spectrum of clinical manifestations from mi-
nor signs and symptoms to local anesthetic systemic 
toxicity (LAST) that can result in disability or even 
death. With an implementation of new regional anes-
thesia techniques and adherence to dosage recommen-
dations and new guidelines for the management of 
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complications, the incidence of severe LA complica-
tions should decrease1.
The objective of this narrative review was to sum-
marize current knowledge concerning complications 
and contraindications of LAs and steroids, update on 
incidence, early recognition of signs and symptoms of 
adverse events, prevention and therapy of complica-
tions with practical recommendations.
Methods
We have searched medical literature published on 
English on PubMed, Ovid Medline® and Google 
Scholar search. We included peer-reviewed profes-
sional articles, review articles, retrospective and pro-
spective studies, case reports, case series published 
from January 2015 to December 2018, but excluded 
editorials and letters to editors, animal experiments, in 
vitro studies, studies in infants and children and data 
available only in abstracts. The search strategy consist-
ed of the following Medical Subject Headings (MeSH) 
terms: Anesthetics, Local; Anesthetics, Local/adverse 
effects; Anesthetics, Local/toxicity; Anesthetics, Lo-
cal/complications. The initial screen was based on titles 
and abstracts of articles on LA adverse effects and 
complications. First, we have read the abstracts of 130 
papers and excluded 90 irrelevant articles. We have 
read 40 full-text articles and excluded articles which 
do not meet inclusion criteria and not mentioning re-
gional anesthesia and pain management. Limitations 
to retrieval of data from case reports include selection 
and reporting bias. Extraction of data from adminis-
trative database and surrogate markers may overesti-
mate the incidence of LA adverse events when com-
pared to clinical registries. In addition, we repeated the 
same search with the same inclusion and exclusion 
criteria in the same databases using MeSH keywords: 
Steroids/adverse effects; Steroids/complications; Re-
gional anesthesia and analgesia. First, we have read the 
abstracts of 74 papers and excluded irrelevant articles. 
We have then read 24 full-text articles and excluded 
articles which do not meet inclusion criteria or not 
mentioning regional anesthesia and pain management.
Results
Out of 130 articles,40 articles were identified and 
twenty seven articles (seventeen review articles, special 
articles, retrospective analysis and ten case reports) 
with relevant information on LA complications (ad-
verse events) were selected. We excluded two articles 
for continuing education and one review of LA effects 
in cutaneous surgery. A critical appraisal was per-
formed based on the twenty four selected studies and 
summarized updated information on LAs complica-
tions and contraindications.
Out of 74 articles on steroid adverse effects and 
complications, 24 articles were identified. We extract-
ed eight most important articles (5 review articles, 2 
case reports and 1 retrospective analysis) to summarize 
updated information on steroid complications and 
contraindications.
Discussion
Local anesthetic complications and contraindications
The present knowledge on adverse effects and com-
plications following administration of LAs in humans 
are derived from animal and in vitro studies, case re-
ports, case series, clinical registries, observational and 
epidemiologic studies. Ethical concerns preclude ran-
domized controlled trials (RCTs) because patients suf-
fering adverse events cannot be recruited to RCT. We 
retrieved relevant information on local anesthetic 
complications published during the last five years in 
order to update the current knowledge on this topic.
Epidemiology of local anesthetic complications
The incidence of LAST is around three per 10,000 
peripheral nerve blocks (PNBs)2. PNBs require larger 
doses of LA than neuraxial blocks, significantly in-
creasing the risk for LAST.In most recently published 
reports, rates of serious cases of LA toxicity (seizures 
with or without cardiac collapse) are 1:10,000 for epi-
dural analgesia but ten times higher for PNBs(1:1000)3. 
Liu et al. 4 identified three LAST cases from 80,661 
patients who received PNBs and found no cases of 
cardiac arrest PNBs (0/1000 PNBs, 95% confidence 
interval [CI] 0–0.05/1000) and 3 cases of seizures 
(0.04/1000 PNBs, 95% CI 0.01– 0.11/1000). Mör-
wald EE, et al. 5searched a large nationally representa-
tive administrative database and determined cumula-
tive rate of patients’ outcomes (cardiac arrest, seizures, 
and use of intralipid on the day of surgery) of 0.18% in 
238,473 (1.8/1000) orthopedic patients for total joint 
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arthroplasties who received PNBs. In this recent retro-
spective cohort study, the incidence of LAST was low 
but clinically meaningful and decreased significantly 
during the study period. Rubin DS et al.6also searched 
a large national database from 1998 to 2013 with 
710,000 patients who had adjunct PNBs placed for 
total joint arthroplasty of the hip, knee and shoulder, 
revealed an average adjusted incidence of 1.04 (95% 
CI 0.49-1.80) LAST events per 1000 PNBs with de-
creasing trend over the study period. Major LAST 
complications were present in 0.22 per 1000 PNBs.
Gitman M and Barrington MJ7determined the inci-
dence of LAST 0.03% or 0.27 (95% CI, 0.21–0.35) 
per 1000 PNBs (denominator of 251.325) from online 
registries with data on ILE therapy. They have been 
established that seizure was the most common adverse 
event (53% from recently published case reports and 
61% from online registries).
The incidence of LAST is likely underreported be-
cause of misdiagnosis, especially in practitioners other 
than anesthetists, lower reporting of minor events, 
atypical and unusual clinical manifestation, delayed 
onset of symptoms as well as publication bias. New 
regional anesthesia techniques reduce the incidence of 
LAST but persistent vigilance is crucial for the pre-
vention and treatment of this life-threatening compli-
cations.
Risk factors, clinical manifestations, prevention  
and treatment of LA complications
Adverse reactions may occur because of dosing er-
ror or rapid absorption of injected LAs in highly vas-
cular tissues. LA toxicity is most often caused by inap-
propriate LA administration such as accidental intra-
vascular injection or multiple injections. Toxic events 
can occur very fast following intravascular injection or 
can be delayed when absorbed from local tissue injec-
tion8. Maximal safety dose of LA should not exceed 
the recommended dose because morbidity and mortal-
ity from LA significantly increases in higher doses. 
Adverse events of LA may be systemic or local. Signs 
and symptoms of systemic toxicity depend on affected 
organ systems. High doses of LAs cause initial clinical 
manifestations of CNS stimulation including circum-
oral and tongue numbness, metallic taste, visual and 
auditory disturbance (eyes-focusing difficulty and tin-
nitus), lightheadedness, drowsiness, confusion, disori-
entation and dizziness. CNS symptoms may progress 
to CNS depression with muscle twitching and convul-
sions, onset of unconsciousness and coma with respira-
tory arrest. Cardiovascular symptoms may be preceded 
by CNS symptoms. Cardiovascular (CV) manifesta-
tions include chest pain, shortness of breath, bradycar-
dia, dysrhythmias, hypotension, syncope, myocardial 
depression and cardiac collapse. Patients with preexist-
ing cardiac conduction abnormalities or heart failure 
are at particular risk.
CNS symptoms are more often associated with li-
docaine use rather than bupivacaine. Nicholas E et al.9 
reported a case of a young man with persistent epi-
staxis. He developed severe lidocaine toxicity resulting 
from a topical anesthesia with 2% lidocaine prior to 
intranasal cautery. Intranasal LA has a variable ab-
sorption and dosing could be difficult. Signs of lido-
caine toxicity included sleepiness, generalized shaking 
episode, nausea, vomiting, bradycardia, and hypoten-
sion, but it was recognized immediately and success-
fully treated with lipid emulsion.
Risk of cardiovascular toxicity is greater with lipo-
philic LA like bupivacaine. Nelson M et al.10presented 
a case of a 66-year-old man with diabetes, hypothy-
roidism, sleep apnea, surgical history of coronary ar-
tery bypass grafting and lobectomy from lung cancer, 
who developed profound and prolonged bradycardia, 
and hypotension immediately after interscalene bra-
chial plexus block with 0.5% bupivacaine for elective 
rotator cuff surgery.
Hematologic reactions include methemoglobin-
emia which is associated with use of benzocaine, prilo-
caine and lidocaine. They are metabolized by the liver 
to ortho-toluidine that converts hemoglobin to met-
hemoglobin. High levels of methemoglobulin lead to 
cyanosis, tachypnea, fatigue, weakness, dizziness and 
syncope. In the case of severe reaction, methylene blue 
and hyperbaric oxygen are the treatment options.
Commonly patients and even medical personnel 
misinterpret and record adverse reactions as an allergy 
to LA. But more likely they are reactions to adjuvants, 
like epinephrine, vasovagal syncope or overdose toxic-
ity. Allergy occurs very rarely and includes rash, urti-
caria and anaphylaxis. Hydrolysis of amino esters by 
cholinesterase results in the release of para-aminoben-
zoic acid which is the main cause of LA acute allergic 
reactions. Amide-type LAs are metabolized in the 
liver and true allergy to amide LAs is very rare. Aller-
gic reactions to amide LAs are mostly attributed to 
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additives which are well-known allergens such as 
metabisulfite or methylparaben. A recent case report 
by Bina B et al.11reported a middle-aged woman with 
documented history of anaphylactic reaction to lido-
caine. True allergy to LA is a contraindication for use 
of other anesthetics from the same chemical classes 
(esters or amides). But her allergist declined to test her 
for ester-type allergies because of previous anaphylac-
tic reactions to amide type LA during testing. The pa-
tient wanted to avoid general anesthesia and dental 
treatment was performed under maxillary infiltration 
with anesthetic mixture of 1% diphenhydramine with 
1:100.000 epinephrine. This emphasizes that patients 
should be informed of alternative medications and 
forms of treatment.
Symptoms of LA sensitivity may be atypical. 
Hayaran N et al. 12presented an unusual case of a young 
man who underwent dental surgery and his lower lip 
mucosa and vestibule was infiltrated with 2% ligno-
caine with adrenaline. The patient had a skin sensitiv-
ity test negative before the surgery. The patient became 
unconscious 20 minutes after injection, actually at the 
end of the surgery. He was unconscious for six hours 
but there was no seizure activity. The blood level of LA 
was inside safety range. An electroencephalogram 
(EEG) showed posterior cortical dysfunction and 
global cerebral depression. After a repeated dose of 
lipid emulsion he regained full consciousness. Detailed 
medical history and discussion with the family re-
vealed that he had already experienced similar loss of 
consciousness for 2 hours after previous dental inter-
vention under local anesthesia. All health-care practi-
tioners should pay attention to atypical and delayed 
manifestations of LA reactions.
Local tissue manifestations of LA toxicity are 
numbness, paresthesia, irreversible conduction block, 
peripheral neurotoxicity (prolonged sensory and mo-
tor deficits) and reversible skeletal muscle damage 
13.Some authors reported rare and unexpected LA 
complications. Neal JM et al.14 documented three cas-
es of LA-induced myotoxicity after continuous adduc-
tor canal block for pain management after total knee 
arthroplasty. The patients developed progressive, pro-
found non-neurogenic weakness of the quadriceps 
muscle. This finding was contrary to previously ac-
cepted opinion that LA-myotoxicity is a subclinical 
disturbance in humans.Myotoxicity risk factors in-
clude higher concentrations, prolonged exposure to 
LA and use of bupivacaine 15.
Local sepsis and coagulopathy are relative contra-
indications to musculoskeletal injections because of 
the higher risk for septic complications or hemor- 
rhage. It is known that infusion of 0.5% bupiva- 
caine with epinephrine through an intra-articular pain 
pump catheter may increase the risk for joint chon-
drolysis16.
Risk factors for local anesthetic adverse effects are: 
individual risk factors, comorbidities (higher pulmo-
nary, cardiac and nervous susceptibilities), taking med-
ications, site of LA administration (injection into a 
vessel-rich tissue), technique of block applied, bolus 
injection without aspiration test, specific local anes-
thetic compound, large total local anesthetic dose, 
timeliness of diagnosis, and treatment with adherence 
to the practice advisory 17,18.
A case report by Tierney KJ et al. 19showed that 
overdoses of LAs can lead to fatal complications. Three 
times the maximum recommended dose of lidocaine 
was used for local infiltration in a middle-aged woman 
during the incision of a labial abscess. Her medical 
history revealed that she had multiple comorbidities 
and was taking atrioventricular nodal blocking agents. 
After the surgery, she vomited and had altered mental 
status with seizure requiring endotracheal intubation. 
Cardiac arrest followed cardiovascular collapse with 
pulseless electrical activity (PEA). The rapid ILE was 
applied and return of spontaneous circulation oc-
curred. She was discharged with no neurological se-
quels. Early recognition of adverse events is critical but 
prevention is the most important. Use of appropriate 
and individualized doses can prevent catastrophic out-
comes.
Individual risk factors include age, weight, comor-
bidities, taking medications, genetic factors, allergies, 
renal and hepatic dysfunction, and cardiac disease. 
Older patients and those with lower skeletal muscle 
mass, which could serve as storage for excess of LA, 
have increased risk for LAST. Elderly patients have 
reduced clearance of LA due to physiologically de-
creased systemic blood flow and liver function leading 
to increased potential for drug accumulation. LA dose 
reduction is not necessary in patients with renal dys-
function except in patients with uremia and metabolic 
acidosis. Despite a higher total plasma LA concentra-
tion in patients with renal dysfunction, the free plasma 
concentration remains unchanged because of the in-
crease in a1 acid glycoprotein concentration. Ropiva-
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caine and levobupivacaine are favorable in patients 
with cardiac disease because of their low cardiotoxic 
potential. However, dose reduction of LA is recom-
mended in advanced heart failure because of increased 
risk for myocardial depression and arrhythmias. He-
patic dysfunction is associated with reduced clearance 
of LAs and higher volume of distribution. Dose ad-
justment of LAs should be taken into consideration in 
advance hepatic dysfunction. Moreover, Lee JE et al. 20 
described an acute liver injury in an older man with 
history of liver transplantation who received regular 
immunosuppressive therapy. The patient underwent 
bilateral total knee arthroplasty under general anesthe-
sia and bupivacaine was injected into each knee for 
postoperative analgesia. Liver enzyme levels increased 
enormously and remained extremely high during the 
first postoperative day. Clinical exam and laboratory 
findings suggested bupivacaine-induced liver injury. 
Anesthesia providers should be aware that local anes-
thetics may disrupt the graft function.
Ropivacaine has a duration of action similar to bu-
pivacaine but it has lower potential for cardiotoxicity. 
It is metabolized in the liver by liver enzymes. Recent-
ly, Tsang TM et al.21demonstrated delayed LAST in a 
66 year old man who underwent thoracotomy for 
pleural biopsies of tumor with continuous paraverte-
bral block for analgesia with ropivacaine.Thirty-seven 
hours after the test dose of LA, the patient developed 
LAST symptoms: perioral tingling, burning sensation 
in legs and penis, agitation, convulsions affecting the 
limbs but no unconsciousness. LAST symptoms were 
resolved soon after stopping LA infusion and admin-
istering intravenous lipid emulsion. Contributing fac-
tors to LAST may be the proximity of the catheter to 
vascular area of tumor and pleural biopsy site, as well 
as, a concomitant prescription of amitriptyline (tricy-
clic antidepressant) which can produce inhibition of 
liver enzymes that metabolize ropivacaine. It is well 
known that ropivacaine may cause vasoconstriction of 
arterioles supplying the CNS and should not be used 
in transforaminal injections because of the risk of 
CNS infarction.
The site of the injection influences the absorption 
of LA with lowest to highest absorption rate as fol-
lows: subcutaneous tissue, brachial plexus, epidural, 
caudal and intercostal spaces. A recent review of case 
reports and registries by Gitman M et al. 7 showed that 
local infiltration analgesia (LIA) in adult patients was 
associated most commonly (17%) with LAST events 
followed by neuroaxial block (13%), lower/upper ex-
tremity block (8.5%), head/neck block (8.5%) and 
paravertebral blocks (8.5%). These results are influ-
enced by total doses of LAs and vascularity of the in-
jected site. As could be expected, bupivacaine was in-
volved more often in LAST cases (36%) than lidocaine 
(26%) and ropivacaine (21%). CNS symptoms were 
the most frequent (77%, 36/47) with seizure as the 
most common feature (53%, 25/47). The highest inci-
dence of LAST (39%) was in patients aged from 20 to 
70 years.
An increased risk for LAST after PNBs was seen 
in shoulder arthroplasty compared with knee and hip 
arthroplasty. Further, risk factors associated with 
LAST are large and medium size hospitals as com-
pared with small hospitals 6.The incidence of systemic 
toxicity after regional block is 1:1000 for nerve sti-
mulator guided block and 1:1600 for ultrasound- 
-guided regional anesthesia (UGRA). The use of ultra-
sound guidance allows for precise visualization of the 
needle, nerves and blood vessels. This allows the use of 
smaller LA volumes and fewer side effects. Also, more 
common in UGRA is an administration of smaller 
volumes in two or more sites around the nerves which 
reduces the risk of injection of the full volume of 
LA intravascularly. In nerve stimulator technique 
full volume is usually given in the same site. UGRA 
reduces intravascular injection of LA but may not be 
widely available in smaller hospitals when compared 
to large health-care centers. Emerging evidence in a 
review of recent literature by Neal JM 22supports 
the effectiveness of ultrasound guided techniques for 
reducing LAST by 65% across its clinical presenta- 
tion from minor to major symptoms. But LAST still 
occurs and continues to be reported as sporadic case 
reports.
In a review of LAST case reports, Vasques F et al.23 
confirmed that comorbidities have an important role 
in predisposing patients to LAST, but 27% of LAST 
events developed in otherwise healthy patients. CNS 
toxicity occurred in 50% of all reported LAST cases, 
mixed CNS and CV toxicity were reported in 36% of 
the cases and 14% cases presented CV toxicity. Late-
onset LAST (longer than 10 minutes) was more fre-
quent (45%) than rapid onset (less than 1 minute, 
18%). This shows that LAST is an unpredictable phe-
nomenon with atypical manifestations from time to 
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time and mandates for vigilance to detect prodromes. 
The most frequent LAST events occurred in operative 
room (69%) and were associated with interscalene 
block (23%) followed by epidural/caudal block (16%). 
Authors concluded that ILE therapy may be under ad-
ministered in current clinical practice.
Protein binding of LAs is decreased during preg-
nancy causing higher sensitivity to LAs. Functional 
changes during pregnancy with influence of hormones 
on cardiac myocytes, increased neuronal sensitivity to 
LAs and engorged epidural veins contribute to higher 
risk for LAST. LAST in an expectant mother who re-
ceived bupivacaine in combined spinal-epidural anal-
gesia for labor started fifty minutes from the first LA 
administration24. She felt metallic taste, tinnitus and 
palpitations. Epidural infusion was stopped immedi-
ately and symptoms were resolved within 10 minutes 
of 20% intralipid administration.
Park H-S et al.8 showed that interscalene brachial 
plexus block (ISB) is contraindicated in patients with 
preexisting contralateral vocal cord palsy or paresis. 
Recurrent laryngeal nerve block is rare, but it is a pos-
sible complication of continuous ISB for shoulder sur-
gery which may lead to acute respiratory failure in pa-
tients with contralateral vocal cord palsy. Authors rec-
ommend detailed medical history, examination of the 
upper airway, ultrasound guided injections of LAs and 
lower concentrations of LAs.
Healthcare providers who administered LAs must 
be familiar with guidelines on the management of 
LAST7. Neal JM et al.,25 showed that non-use of 
American Society of Regional Anesthesia and Pain 
Medicine (ASRA) checklist as a reminder of thera-
peutic interventions worsens therapeutic performance 
during LAs adverse events. Updated ASRA practice 
advisory guidelines26 from 2017, recommend airway 
protection first and then start of ILE because hy- 
poxia, hypercapnia and acidosis can promote LAST. 
ILE therapy is simplified and easy to memorize. Initial 
bolus of 100 mL lipid emulsion was followed by the 
infusion rate of 200 to 250 mL over 15 to 20 minutes 
for patients weighing more than 70 kg. Benzodiaze-
pines are the first choice for seizure treatment but 
small boluses of propofol may be used. Special con-
siderations in cardiac arrest treatment include reduced 
doses of epinephrine (≤1mcg/kg) but medications 
such as vasopressin, beta and calcium channel block- 
ers and local anesthetics (lidocaine and IB antiar-
rhythmics) are contraindicated. If ventricular arrhyth-
mias develop, amiodarone is preferable. If ILE and 
vasopressor therapy failed, cardiac pacing and cardio-
pulmonary bypass may improve the outcome. Moni-
toring of vital signs lasts for 4 to 6 hours after cardio-
vascular adverse event and at least 2 hours after CNS 
adverse events 13,26.
The prevention of adverse events should be the pri-
mary goal. Many complications could be avoided by 
adherence to the recommended LA doses using the 
lowest effective doses, as well as appropriate adminis-
tration technique with incremental injection and test-
ing doses. Maintaining verbal contact with the patient 
during the entire procedure serves as a close monitor-
ing. Patients’ cooperation is also important. They can 
be informed with additional educational materials and 
online resources (lipidrescue.org).
Recently published case reports suggest a trend to-
ward atypical and delayed clinical manifestations. The 
major causes may be in more precise nerve localization 
with ultrasound guidance of the needle and conse-
quently lower incidence of intravascular injection and 
local infiltration techniques with slower uptake into 
systemic circulation. However, there is a need for con-
tinued education of health-care providers, including 
anesthetists, surgeons, dentists, emergency medicine 
physicians and others who are involved in LA admin-
istration about prevention, recognition and treatment 
of acute and chronic adverse effects.
Steroids
Corticosteroids are routinely injected into soft tis-
sues, tendon sheaths, bursae and joints. Corticosteroids 
are esters or non-esters. Corticosteroid esters (e.g. 
methylprednisolone acetate, triamcinolone acetonide, 
betamethasone acetate) are insoluble in water and 
form microcrystalline suspensions. They are hydro-
lyzed by cellular esterases to release the active com-
pounds. As a result, they have longer half-lives and 
prolonged activity in the joints when compared with 
non-esters. Corticosteroid non-esters (e.g. dexametha-
sone and betamethasone) are freely soluble in water 
and preparations are clear (non-particulate). Non-es-
ters are taken by cells rapidly and have a faster onset of 
activity but shorter duration of action when compared 
with esters 27.
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Epidemiology, clinical manifestations,  
prevention and treatment of steroid complications
Adverse effects of corticosteroids are rare, but when 
they occur, the consequences could be serious. Aseptic 
technique should be strictly applied to keep the inci-
dence of septic arthritis as low as 0.01-0.03%. A septic 
joint is associated with significant morbidity and mor-
tality of 11.5 %. Post injection “flare” mostly caused by 
microcrystalline steroid esters is the most common 
adverse effect with prevalence of 2-25%. In case of a 
local increase of inflammation longer than 24 hours, a 
joint infection must be excluded by aspiration. “Flare” 
develops within hours following injection and lasts 2-3 
days. Extraarticular injections may be associated with 
local tissue necrosis, calcification, as well as tendon 
rupture that could be caused by inhibition of tenocyte 
proliferation. These complications could be minimized 
by injection with caution from an experienced practi-
tioner. Soft tissue injections may cause skin depigmen-
tation, fat necrosis, as well as, cutaneous atrophy which 
may be effectively treated by local infiltration of nor-
mal saline 27.
Multiple injections into the joint increase the risk 
of articular cartilage loss and the incidence is 0.7-3%.
Steroid toxicity is related to both the average dose and 
cumulative duration of use. Corticosteroids have a 
time dependent and dose dependent deleterious ef-
fects on articular cartilage and minimal effective doses 
should be used. Doses should be estimated according 
to the size of injected joint and the frequencies of in-
jections should be limited28.
Systemic effects of steroid soft tissue or intraarticu-
lar injections have small clinical significance. Patients 
should be advised to avoid surgery and risk of trauma 
or infections within two weeks after steroid injections 
because of increased risk of adrenal crisis. Diabetic pa-
tients should be warned to expect hyperglycemia for 2 
to 5 days following steroid injections. Facial flushing 
accompanied with coldness, shaking and headaches 
may occur secondary to histamine release and symp-
toms can be reduced with antihistamines and choice of 
another steroid 29.
In a recent systemic review and meta-analysis of 
eight randomized controlled trials (RCTs) including 
771 patients of which 366 patients received epidural 
steroids (particulate and nonparticulate), Bhatia A et 
al. 30reported sporadic occurrence of adverse effects in 
only two RCTs such as hyperglycemia, myopathy and 
neurologic injuries. It is important for the anesthetists, 
radiologists, orthopedic surgeons and pain physicians 
to be aware that a rare adverse event may suddenly oc-
cur after steroid injection. A recent case report de-
scribed segmental spinal myoclonus during lumbar 
transforaminal epidural injection with particulate ste-
roid triamcinolone 31. Adverse central nervous system 
events such as brain and spinal cord infarction and 
paraplegia are caused by vascular injuries, embolic in-
farction after particulate steroid intraarterial adminis-
tration and neurotoxicity from preservatives and drug 
vehicles. New challenges arise when practitioners per-
form interventional procedures on patients who are 
anticoagulated. Even with adherence to guidelines for 
performing neuroaxial injections in the setting of anti-
coagulants, patients may develop an epidural hemato-
ma and paraplegia after thoracic epidural steroid injec-
tion32. Combination of LAs and steroids improves 
postoperative analgesia. A recent meta-analysis of 
fourteen studies with a total of 1,022 patients showed 
that lower doses of 4-5 mg perineural dexamethasone 
added to LA for brachial plexus block improves post-
operative analgesia without increasing the incidence of 
complications including nausea, hoarseness, dyspnea 
and Horner’s syndrome 33.
Contraindications to the use of corticosteroid in-
jections may be absolute or relative. Absolute contrain-
dications are local infection, sepsis and bacteremia to 
avoid spreading of infection. Steroids inhibit bone 
healing and should be avoided in the case of intraar-
ticular fracture. Steroids are contraindicated in joint 
instability because of the risk of subchondral osteone-
crosis and weakening of the joint structures. Relative 
contraindications are: juxta-articular osteoporosis be-
cause of the fear for further decrease of bone density, 
coagulopathy, injection three times per year or within 
six weeks29. There is an increased risk of intraoperative 
and postoperative joint infection if total hip arthro-
plasty is performed within 3 months of hip steroid in-
jection. New recommendations consider delaying elec-
tive total hip arthroplasty for 3 months after an injec-
tion to avoid this elevated risk of infection34.
According to the recent literature, adverse events 
associated with steroid injections in soft tissue and 
joints in regional analgesia and pain management are 
rarely reported. The indication for pain treatment 
Tatjana Šimurina et al. Local anesthetic and steroid complications
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should be justified and patients informed of the bene-
fits, risk of adverse effects and therapeutic alternatives.
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Sažetak
LOKALNI ANESTETICI I STEROIDI: KONTRAINDIKACIJE I KOMPLIKACIJE.  
TRENUTNI KLINIČKI PREGLED
T. Šimurina, B. Mraović, M. Župčić, S. Graf Župčić i M. Vulin
Cilj rada je analizirati učestalost i karakteristike klinički važnijih nusučinaka lokalnih anestetika i kortikosteroida u regio-
nalnoj anesteziji te liječenju akutne i kronične boli temeljem medicinske literature objavljene unatrag pet godina. Pretražene 
su baze medicinskih podataka na engleskom jeziku pomoću PubMed, Ovid Medline®i Google Scholar-a za razdoblje od 
početka 2015. do kraja 2018. godine. Ovaj narativni pregledni članak donosi pregled komplikacija i kontraindikacija za 
 lokalne anestetike i kortikosteroide s naglaskom na sadašnje stavove u pogledu prevencije, rane dijagnoze i liječenja nus-
pojava.
Ključne riječi: lokalni anestetici, nuspojave, toksičnost, komplikacije, steroidi, regionalna anestezija i analgezija
